$16.23
1.70% today
Nasdaq, Feb 05, 04:18 pm CET
ISIN
US0327241065
Symbol
ANAB
Sector
Industry

AnaptysBio, Inc. Stock price

$16.51
+1.21 7.91% 1M
-15.86 49.00% 6M
+3.27 24.70% YTD
-7.56 31.41% 1Y
-14.86 47.37% 3Y
+1.47 9.77% 5Y
-0.49 2.88% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
-0.15 0.90%
ISIN
US0327241065
Symbol
ANAB
Sector
Industry

Key metrics

Market capitalization $502.38m
Enterprise Value $439.32m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7.68
P/S ratio (TTM) P/S ratio 8.79
P/B ratio (TTM) P/B ratio 5.95
Revenue growth (TTM) Revenue growth 282.17%
Revenue (TTM) Revenue $57.17m
EBIT (operating result TTM) EBIT $-140.08m
Free Cash Flow (TTM) Free Cash Flow $-103.43m
Cash position $430.12m
EPS (TTM) EPS $-6.07
P/E forward negative
P/S forward 8.98
EV/Sales forward 7.86
Short interest 29.61%
Show more

Is AnaptysBio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

AnaptysBio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a AnaptysBio, Inc. forecast:

9x Buy
75%
3x Hold
25%

Analyst Opinions

12 Analysts have issued a AnaptysBio, Inc. forecast:

Buy
75%
Hold
25%

Financial data from AnaptysBio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
57 57
282% 282%
100%
- Direct Costs 2.40 2.40
1% 1%
4%
55 55
335% 335%
96%
- Selling and Administrative Expenses 38 38
2% 2%
67%
- Research and Development Expense 154 154
27% 27%
270%
-138 -138
6% 6%
-241%
- Depreciation and Amortization 2.40 2.40
1% 1%
4%
EBIT (Operating Income) EBIT -140 -140
6% 6%
-245%
Net Profit -166 -166
12% 12%
-290%

In millions USD.

Don't miss a Thing! We will send you all news about AnaptysBio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AnaptysBio, Inc. Stock News

Neutral
GlobeNewsWire
2 days ago
SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025 at 1:00pm ET / 10:00am PT.
Neutral
GlobeNewsWire
2 days ago
WASHINGTON and SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab (IL-36R antagonist mAb), which has successfully completed two registration-enabling global Phase 3 trials, GEMINI-1 and GEMINI-2,...
Neutral
PRNewsWire
2 days ago
Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular Psoriasis Vanda expects to immediately begin preparing BLA and MAA applications for the US and EU Anaptys to receive $15 million from Vanda, comprised of a $10 million upfront payment and $5 million for existing drug supply Anaptys to receive a 10% royalty on global net sales of imsidolimab WASHINGTON and ...
More AnaptysBio, Inc. News

Company Profile

AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its products pipeline include ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Head office United States
CEO Daniel Faga
Employees 117
Founded 2005
Website www.anaptysbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today